94 results about "Fusobacterium nucleatum" patented technology

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention discloses a lactobacillus casei KC88, and the preservation number of the lactobacillus casei KC88 is CGMCC (China General Microbiological Culture Collection Center) No.32107. Meanwhile, the invention also discloses a screening process and application of the strain. According to the lactobacillus casei KC88 provided by the invention, the expression of a Cdl gene with fusobacterium nucleatum can be down-regulated, and the expression of a Mgl gene of porphyromonas gingivalis can be down-regulated. At the same time, the lactobacillus casei KC88 can inhibit the production of pathogenic bacteria biological membranes and reduce the production of volatile sulfides. And the inactivated surface protein of the casei casei KC88 can inhibit the formation of a pathogenic bacterium biological membrane. Therefore, the lactobacillus casei KC88 viable bacteria and the thermally inactivated bacteria have the effects of relieving breath and improving gastrointestinal functions, and can be applied to the fields of medicines, health care products and the like.

The invention provides a nano-drug based on atomic layer deposition and a preparation method of the nano-drug, mesoporous silica is taken as a carrier, bimetallic nanoparticles are precisely deposited through ALD, and chemotherapeutic drugs and antibacterial components are loaded by combining amination and targeted PEG modification, so that the following functions are realized: (1) H2O2 in a tumor microenvironment is catalyzed to generate reactive oxygen species (ROS); removing fusobacterium nucleatum and damaging a biological membrane of the fusobacterium nucleatum; (2) GSH is consumed through Fenton reaction, and tumor drug resistance is reversed; and (3) the drug is released in pH response, and tumor cells are accurately killed. The invention further provides application of the nano-drug based on atomic layer deposition in treatment of related drug-resistant colorectal cancer induced by fusobacterium nucleatum, the process is controllable, the biocompatibility is excellent, the treatment effect on the drug-resistant colorectal cancer is remarkably improved, and the nano-drug has wide clinical application prospects.

The invention provides a Lactobacillus casei GG002, a bacteriocin solution of the Lactobacillus casei GG002, freeze-dried powder of the Lactobacillus casei GG002 and application of the bacteriocin solution and the freeze-dried powder of the Lactobacillus casei GG002 to treatment of oral ulcer, and belongs to the technical field of microorganisms. The invention finds that the lactobacillus casei GG002 can inhibit streptococcus mutans, fusobacterium nucleatum and porphyromonas gingivalis, and has the effect of treating oral ulcer. The invention further provides a bacteriocin solution, freeze-dried powder and metagen of the casei casei GG002, and the bacteriocin solution, the freeze-dried powder and the metagen can be used for effectively treating the oral ulcer.

The invention relates to the technical field of microorganisms, in particular to space breeding combined lactobacillus salivarius ZK-88-S and application thereof. The combined lactobacillus salivarius ZK-88-S disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2024, and the preservation number is CGMCC No.33181; the combined lactobacillus salivarius ZK-88-S can inhibit escherichia coli, staphylococcus aureus, candida albicans, pseudomonas aeruginosa, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus salivarius, streptococcus gordoni or actinomyces naessii, and can be applied to preparation of medicines, daily necessities or health-care foods for oral treatment and oral cleaning.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a model with fusobacterium nucleatum damaged mouse intestinal tract organoid, and the construction method comprises the following steps: separating mouse intestinal tract organoid; obtaining a culture supernatant with fusobacterium nucleatum; obtaining a cell-free extract with fusobacterium nucleatum; viable bacteria with fusobacterium nucleatum are obtained; and treating the mouse intestinal organ with the fusobacterium nucleatum culture supernatant or the fusobacterium nucleatum cell-free extract or the fusobacterium nucleatum viable bacteria to obtain the model of the mouse intestinal organ damaged by the fusobacterium nucleatum. The construction method of the organ-like model with the fusobacterium nucleatum damaged intestinal tract is simple, operability and convenience can be increased for further research on a regulation mechanism of the fusobacterium nucleatum damaged intestinal tract, and a reliable and accurate research tool is provided for gastrointestinal diseases such as inflammatory bowel diseases and colorectal cancer.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.

The invention discloses application of macrophage exosome molecules induced by fusobacterium nucleatum, and belongs to the technical field of molecular biology. The nucleotide sequence of the macrophage exosome molecule induced by fusobacterium nucleatum is 5 '-ACUGGCUAGGGAAAAUGAUUGGAU-3', and the macrophage exosome molecule can be applied to preparation of a preparation for inducing VSMC cells to be converted into macrophage-like phenotypes, can regulate and control the atherosclerosis process, and provides a new thought and theoretical basis for further research of exosome in the atherosclerosis progress process.

The invention relates to the field of tumor immunotherapy, in particular to an mRNA vaccine targeting fusobacterium nucleatum membrane protein FomA and application of the mRNA vaccine in esophageal squamous cell carcinoma immunotherapy. The vaccine comprises a nucleotide sequence for coding a specific epitope of FomA, and the specific epitope contains 1-10'GGSGGGGSGG 'repetitive sequences and has homology gt in different strains; 95%. The mRNA is encapsulated in lipid nanoparticles (the particle size is 80-150 nm, the polydispersity coefficient is lt; and the liposome is composed of 38-42% of cationic lipid, 18-22% of neutral lipid, 33-37% of cholesterol and 3-5% of PEG modified lipid, and the encapsulation efficiency is 85-95%. The vaccine can specifically reduce the abundance of fusobacterium in tumors by 72.4 + / -8.0%, the tumor microenvironment is converted into an immune activation type, and the proportion of CD8 + T cells is increased from 5.2 + / -1.0% to 14.5 + / -2.0%. When the compound is combined with a PD-1 inhibitor, the objective remission rate reaches 70%, the tumor volume is reduced by 78.5 + / -8.0%, and the compound is suitable for treating clostridium-enriched esophageal squamous carcinoma.

Compositions and methods useful in preventing, reducing, delaying, diagnosing, and treating cancer and in studying the effects of cancer-associated microbes are described. The compositions and methods can be used to detect and study cancer-associated microbes and / or attenuate, modify, or utilize the effects of the cancer-associated microbes. Compositions and methods to modulate the effects of the cancer-associated microbes include the use of vaccines, inhibitors, genetic engineering, immunotherapy, cell therapy, and chemotherapeutic treatments.

The invention discloses composite yolk immunoglobulin antibody toothpaste and a preparation method thereof, and the toothpaste comprises the following components in percentage by mass: 0.01-1.0% of yolk immunoglobulin; 10-70% of a humectant; 0.01%-0.5% of an acid-base buffer agent; 0.01%-0.5% of a taste improver; 0.1%-3% of a thickening agent; 5-50% of a friction agent; 0.1-5% of a foaming agent; 0.01%-0.5% of an appearance improver; 0.1 to 2.0 percent of essence; and the balance of water. Wherein the egg yolk immune globulin is a composite specific egg yolk antibody for resisting porphyromonas gingivalis, fusobacterium nucleatum and prevotella intermedia. Starting from three key pathogenic bacteria causing periodontal diseases, the egg yolk composite antibody resisting porphyromonas gingivalis and having specificity of fusobacterium nucleatum and prevotella intermedius is added into a toothpaste formula, and the effects of inhibiting bacteria, preventing and relieving oral inflammation, repairing gingiva and the like are achieved in a tooth brushing mode.

The invention belongs to the field of biological medicine, and particularly relates to a fusobacterium nucleatum FtsZ protease inhibitor and application thereof. On the basis of the idea of new use of old drugs, drugs approved by FDA are subjected to structure-based virtual screening and molecular dynamics simulation, and sorafenib, ponatinib, ceritinib and ibastine can be stably combined to active sites of fusobacterium nucleatum FtsZ protease; in-vitro experiments also show that sorafenib, ponatinib, ceritinib and ibastine are inhibitors with the fusobacterium nucleatum FtsZ protease, so that new antibacterial applications of sorafenib, ponatinib, ceritinib and ibastine are explored. The invention not only provides a new angle for antibiotic discovery, but also provides an example for rapid development of a novel FtsZ protease inhibitor.

The present disclosure discloses a strain of Lactobacillus fermentum capable of preventing and / or treating periodontitis and an application thereof, belonging to the field of microbiology technology. The present disclosure has screened to obtain a strain of L. fermentum CCFM1139. The L. fermentum CCFM1139 can alleviate periodontitis by inhibiting formation of mixed bacterial biofilms of Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum, thereby reducing the amount of biofilm by 52.45%, and can reduce the content of TNF-α from 131.37 pg / mL to 83.31 pg / mL and IL-8 from 147.70 pg / mL to 121.12 pg / mL in a periodontitis cell model, reduce colonization of the P. gingivalis and the F. nucleatum in the oral cavity by 1-2 orders of magnitude, and reduce the amount of the alveolar bone resorption from 1838.0 μm to 805.7 μm.

The application belongs to the field of chemical biology, and relates to a Fusobacterium nucleatum single-stranded DNA aptamer and a screening method and kit. The nucleotide sequence of the aptamer is as follows: 5'-TGACTGACGACGACTCCGCX1GX2X3X4GX5AGX6X7X8X9X 10 CGTX 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 GX 24 X 25 X26X 27 X 28 AX 29 X 30 GX 31 X 32 X 33 X 34 X 35 X 36 AGACTGCTCGAGCTG-3'. The aptamer obtained by the application has the characteristics of simple operation, high sensitivity, low manufacturing cost and strong specificity, and has a broad application prospect in the detection of Fusobacterium nucleatum.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

The present invention relates to a drug carrier based on bacterial cell membrane and its preparation method and application. The nano drug composition of the present invention includes a drug and a bacterial cell membrane drug-carrying system, wherein the bacterial cell membrane drug-carrying system encapsulates the drug; the bacterial cell membrane drug-carrying system includes a bacterial cell membrane and a liposome; the bacterial cell membrane is wrapped outside the liposome; it can be efficiently enriched in the tumor site, release a drug that can kill Fusobacterium nucleatum, effectively alleviate the immunosuppressive microenvironment caused by Fusobacterium nucleatum, restore the response of colon cancer to anti-cytotoxic T lymphocyte-associated antigen 4 therapy and anti-programmed death receptor therapy, and can also effectively alleviate the resistance of Fusobacterium nucleatum to chemotherapy drugs, and restore the responsiveness of the tumor to the chemotherapy drug 5-fluorouracil. The nano drug composition can also kill a variety of bacteria in the breast cancer tumor site to alleviate tumor metastasis caused by tumor bacteria, and restore the responsiveness of the tumor to the combined chemotherapy regimen.

The invention provides a pathogenic fusobacterium nucleatum adapted to an acid environment and a culture method and application thereof, a new strain is obtained through culture of acid adaptive evolution F.nucleatum, and the new strain is named fusobacterium nucleatum LA57 and F.nucleatum LA57 and preserved in Guangdong Microbial Culture Collection Center with the preservation number of GDMCC No.64989. According to the invention, the new strain is named F.nucleatum LA57 and preserved in Guangdong Microbial Culture Collection Center with the preservation number of GDMCC No.64989; the bacterial strain can improve the proliferation capacity of colorectal cancer cells and improve the erosion capacity of colorectal cancer; the method can be applied to a real process experiment of reducing bacterial infected tumor cells in tumor tissues, and has important significance on further revealing the microbial pathogenic effect in the CRC generation and development process and improving the tumor prevention and treatment effect.

To provide honey that has higher antibacterial activity to at least one kind of bacterium selected from the group consisting of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia.SOLUTION: A periodontal disease preventive and / or foul breath preventive contain acacia honey and / or honeydew honey as an active ingredient.SELECTED DRAWING: None

The invention discloses an antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems, and belongs to the technical field of biology. According to the invention, two cationic antibacterial peptides LR18 and LR18-2 with amphiphilic alpha-helical structures are designed from the beginning. The two antibacterial peptides have good antibacterial and bactericidal activity on oral periodontal pathogenic bacteria (including fusobacterium nucleatum, porphyromonas gingivalis and streptococcus mutans), the minimum inhibitory concentration (MIC) is 62.5-500 [mu] g / mL, and the minimum bactericidal concentration (MBC) is 62.5-2000 [mu] g / mL. The structure is simple, the chemical synthesis difficulty is low, a high-purity product can be directly synthesized, the cell hemolytic activity is low, the safety is high, the product can be used for preparing oral antibacterial drugs and / or oral care products, and oral diseases are prevented and treated by inhibiting the growth of oral periodontal pathogenic bacteria.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention belongs to the technical field of biological agents, and particularly relates to composite IgY antibody freeze-dried powder for pet oral hygiene and a preparation method and application thereof. Oral bacteria such as prevotella intermedia, porphyromonas gingivalis, streptococcus mutans, actinomyces viscosus and fusobacterium nucleatum are selected in a targeted manner, the bacteria are used for preparing a composite IgY antibody, the composite IgY antibody is combined with the freeze-drying agent optimized by the invention, and the antibody freeze-dried powder is prepared by immunizing laying hens, so that the range of the bacteria is wider, and the immunogenicity of the laying hens is improved. The compound IgY antibody obtained by the prepared compound IgY antibody freeze-dried powder is high in activity, and the compound IgY antibody freeze-dried powder has good re-dissolvability, stability, affordability, simplicity and convenience, can maintain titer at-20 DEG C for more than two years, and is convenient to store, transport and popularize. Compared with the prior art, the composite IgY antibody freeze-dried powder aims at wider flora, can effectively resist canine oral malignant bacteria, and can be used as an additive to be added into oral health products such as toothpaste and mouth wash.

The invention discloses a preparation method of a gold (I) coordination compound and an application in antibiosis, a series of gold (I) coordination compounds have obvious inhibition effects on common oral germs such as staphylococcus aureus (S.a), porphyromonas gingivalis (P.g) and fusobacterium nucleatum (F.n), and the action effects of the gold (I) coordination compounds are better than those of common oral antibacterial drug chlorhexidine; the invention discloses improved preparation and purification methods of the gold (I) complexes, and the gold (I) complexes have good bacteriostatic activity on common oral germs.

The application discloses application of an ABC transporter substrate-binding protein in preparation of an anti-Fusobacterium nucleatum vaccine and belongs to the technical field of biotechnology.The ABC transporter substrate-binding protein (ABC-sbp) is a rnlrABC-sbp without a leading region which is expressed by an E. coli expression system, and the amino acid sequence of the rnlrABC-sbp is shown as SEQ ID NO. 2. In addition, the application further discloses a genetic engineering subunit vaccine against the Fusobacterium nucleatum, which comprises the rnlrABC-sbp protein with the amino acid sequence shown as SEQ ID NO. 2 and an adjuvant. The genetic engineering subunit vaccine against the Fusobacterium nucleatum prepared by using the rnlrABC-sbp protein can stimulate the body to produce a large amount of antibodies, resist the attack of the Fusobacterium nucleatum, reduce the damage of the body and improve the survival rate, and has important application value in the field of prevention and treatment of the Fusobacterium nucleatum infection.

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a preparation method and application of responsive nano-particles for targeted removal of fusobacterium nucleatum and a biological membrane of the fusobacterium nucleatum. The ERPNPs is formed by self-assembly of PEG (polyethylene glycol)-b-PCL (polycaprolactone), Pep-PAE (polycaprolactone)-b-PCL (polycaprolactone) and (PBA / PAE)-b-PCL, and the ERPNPs carry rifampicin and gallocatechin gallate together. The nano-system exposes FadA target peptide in an acidic tumor microenvironment, accurately recognizes Fn and synergistically sterilizes and disperses a biological membrane, so that an immunosuppression microenvironment is reversed, and the nano-system has an important application prospect in the development of anti-CRC drugs.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

The invention relates to the technical field of molecular diagnosis and early screening of tumors, and particularly discloses a plasma circulating microbial marker for early screening of lung cancer and application of the plasma circulating microbial marker. The marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and haemophilus parainfluenza (Haemophilus parainfluenza), and the marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and Haemophilus parainfluenza (Haemophilus parainfluenza). According to the method, nine characteristic microbial markers are detected in combination with a low Pass WGS technology, a high-precision diagnosis model is constructed through a machine learning algorithm, the established diagnosis model has excellent stability and clinical applicability, efficient recognition of early lung cancer can be achieved, and the detection cost can be greatly reduced.

This invention discloses a dimetronidazole derivative or its pharmaceutical salt, with one of the following general structural formulas: The compounds of this invention exhibit good antibacterial activity and specificity against *Fusobacterium nucleatum* in in vitro antibacterial activity tests; derivative B2 has excellent in vitro antibacterial activity and selectivity against *Fusobacterium nucleatum*. In vivo studies using a mouse xenograft model of colorectal cancer have shown that compound B2, when used alone, has a certain antitumor effect against xenografts caused by *Fusobacterium nucleatum*. Furthermore, when compound B2 is administered in combination with a PD-1 antibody, it exhibits excellent in vivo antitumor activity and can effectively reverse the resistance of *Fusobacterium nucleatum*-infected colorectal cancer to PD-1 antibodies. The compounds of this invention can be used to treat colorectal cancer caused by *Fusobacterium nucleatum*, as well as tumor metastasis and drug resistance that occur during treatment.

The invention relates to the field of microorganisms, in particular to lactobacillus paracasei MG-T209 capable of improving oral health, improving intestinal health and regulating immunity and application of the lactobacillus paracasei MG-T209. The preservation number of the lactobacillus paracasei MG-T209 is CGMCC (China General Microbiological Culture Collection Center) No.35096, the preservation time of the lactobacillus paracasei MG-T209 is 2025-07-03, and the lactobacillus paracasei MG-T209 is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. According to the invention, the lactobacillus paracasei MG-T209 can inhibit harmful microorganisms, such as streptococcus mutans, fusobacterium nucleatum, porphyromonas gingivalis and candida albicans; the microbial agent containing the lactobacillus paracasei MG-T209 can improve oral problems such as bad breath, halitosis, gingival bleeding, tooth sensitivity, dental plaque and oral ulcer.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus rhamnosus A25040 with an antibacterial function as well as a preparation and application of the lactobacillus rhamnosus A25040. The lactobacillus rhamnosus A25040 provided by the invention has the advantages that the lactobacillus rhamnosus A25040 can be used for treating enteropathogenic bacteria, gastrointestinal pathogenic bacteria and oral pathogenic bacteria; particularly, the antibacterial and bactericidal effects on escherichia coli, helicobacter pylori, staphylococcus aureus, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus gordoni, streptococcus sanguis, streptococcus mitis, streptococcus suvidensis subspecies and streptococcus suvidensis subspecies are relatively strong; active substances secreted by the strain have good thermal stability, enzyme tolerance and gastrointestinal fluid tolerance, and the strain shows excellent oxidation resistance. The lactobacillus rhamnosus A25040 disclosed by the invention has broad-spectrum bacteriostasis and oxidation resistance, does not have hemolysis capacity, can be widely applied to functional food development, and has important application value in the field of biological medicines and daily chemical products.